Abstract
G-protein coupled receptors (GPCRs) represent important targets for drug discovery because they participate in a wide range of cellular signalling pathways that play a role in a variety of pathological conditions. The characterization of the patho-physiological profile and functional roles of new receptors is highly dependent on the availability of potent and selective ligands and new screening assays. The study of the pharmacological profile of new chemical entities is very important in order to predict the activity of drugs and their clinical adverse effect in humans. In the last decade, a large number of new in vitro radiolabel-free assays were developed and relevant information on diseases was upgraded. In particular, radiolabel-free assays led significant easy to handle and safer tools for operators. The aim of this review is to analyze these assays in terms of new drug activity and toxicology prediction and translation of non-clinical findings to humans in order to provide a powerful tool to aid drug development.
Keywords: AlphaScreen, β-arrestin, FRET, GPCRs, HTRF, Immunoassays, In vitro assays, SPR.
Mini-Reviews in Medicinal Chemistry
Title:Overview on Radiolabel-Free in vitro Assays for GPCRs
Volume: 17 Issue: 1
Author(s): Michela Buccioni, Claudia Santinelli, Piero Angeli, Diego Dal Ben, Catia Lambertucci, Ajiroghene Thomas, Rosaria Volpini and Gabriella Marucci
Affiliation:
Keywords: AlphaScreen, β-arrestin, FRET, GPCRs, HTRF, Immunoassays, In vitro assays, SPR.
Abstract: G-protein coupled receptors (GPCRs) represent important targets for drug discovery because they participate in a wide range of cellular signalling pathways that play a role in a variety of pathological conditions. The characterization of the patho-physiological profile and functional roles of new receptors is highly dependent on the availability of potent and selective ligands and new screening assays. The study of the pharmacological profile of new chemical entities is very important in order to predict the activity of drugs and their clinical adverse effect in humans. In the last decade, a large number of new in vitro radiolabel-free assays were developed and relevant information on diseases was upgraded. In particular, radiolabel-free assays led significant easy to handle and safer tools for operators. The aim of this review is to analyze these assays in terms of new drug activity and toxicology prediction and translation of non-clinical findings to humans in order to provide a powerful tool to aid drug development.
Export Options
About this article
Cite this article as:
Buccioni Michela, Santinelli Claudia, Angeli Piero, Ben Dal Diego, Lambertucci Catia, Thomas Ajiroghene, Volpini Rosaria and Marucci Gabriella, Overview on Radiolabel-Free in vitro Assays for GPCRs, Mini-Reviews in Medicinal Chemistry 2017; 17 (1) . https://dx.doi.org/10.2174/1389557516666160808120207
DOI https://dx.doi.org/10.2174/1389557516666160808120207 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Bosentan in Pediatric Patients with Pulmonary Arterial Hypertension
Current Vascular Pharmacology The Impact of Metabolic Disease Associated with Metabolic Syndrome on Human Pregnancy
Current Pharmaceutical Biotechnology Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets NLRP3 Is Involved in Ischemia/Reperfusion Injury
CNS & Neurological Disorders - Drug Targets Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches
Current Pharmaceutical Design Blood Pressure and Vascular Alterations with Growth in Childhood
Current Pharmaceutical Design Pharmaconutrition with Omega-3 Fatty Acids: Status Quo and Further Perspectives
Mini-Reviews in Medicinal Chemistry Cardiovascular Effects of Modulators of Soluble Guanylyl Cyclase Activity
Cardiovascular & Hematological Agents in Medicinal Chemistry Steroids and Vasopressor-Resistant Hypotension in Preterm Infants
Current Pediatric Reviews Glucagon-Like Peptide-1 as a Key Regulator of Lipid and Lipoprotein Metabolism in Fasting and Postprandial States
Cardiovascular & Hematological Disorders-Drug Targets From Antidepressant Drugs to Beta-Mimetics: Preclinical Insights on Potential New Treatments for Neuropathic Pain
Recent Patents on CNS Drug Discovery (Discontinued) Respiratory Gas Exchange During Exercise in Children with Congenital Heart Disease: Methodology and Clinical Concepts
Current Respiratory Medicine Reviews Feasibility of Transcutaneous Method for Carbon Dioxide Monitoring in an Intensive Care Unit
Current Respiratory Medicine Reviews Dexmedetomidine: A Novel Anesthetic Agent for Middle Ear Surgery
Recent Patents on CNS Drug Discovery (Discontinued) An Overview of the Effect of Weight Loss on Cardiovascular Autonomic Function
Current Diabetes Reviews Global Cerebral Ischemia: Synaptic and Cognitive Dysfunction
Current Drug Targets Resuscitation of the Patient with the Functionally Univentricular Heart
Current Pediatric Reviews Biomarkers of Acute Kidney Injury in Critical Care Medicine: A Literature Review Based on Recent Patent Applications
Recent Patents on Biomarkers Xanthine Oxidase Inhibitors the Unappreciated Treatment for Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Diagnostic Tools, Biomarkers, and Treatments in Diabetic polyneuropathy and Cardiovascular Autonomic Neuropathy
Current Diabetes Reviews